AF
LFCR icon

Amalgamated Financial’s Lifecore Biomedical LFCR Stock Holding History

Amalgamated Financial’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$37K Buy
+3,163
New +$35.2K ﹤0.01% 2549

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Financial's LFCR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Lifecore Biomedical (LFCR) in Q1 2022: 3,163 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #2549 among its holdings.

97 funds tracked by Wall St. Rank hold LFCR as of Q1 2022.

  • Amalgamated Financial held 3,163 shares of Lifecore Biomedical worth $37K as of Q1 2022.
  • Lifecore Biomedical was a new Amalgamated Financial position in Q1 2022.
  • Lifecore Biomedical made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2549 holding.
  • 97 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.